YOCHAI BIRNBAUM to Drug Therapy, Combination
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Drug Therapy, Combination.
Connection Strength
1.129
-
Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians. Expert Rev Cardiovasc Ther. 2024 Sep; 22(9):483-491.
Score: 0.168
-
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovasc Drugs Ther. 2024 06; 38(3):605-619.
Score: 0.145
-
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Cell Physiol Biochem. 2019; 53(6):961-981.
Score: 0.113
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
Score: 0.108
-
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
Score: 0.074
-
Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther. 2011 Dec; 25(6):505-15.
Score: 0.069
-
Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
Score: 0.062
-
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone. Cardiovasc Drugs Ther. 2008 Dec; 22(6):429-36.
Score: 0.056
-
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther. 2008 Mar; 13(1):72-9.
Score: 0.054
-
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007 Oct; 21(5):321-30.
Score: 0.052
-
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006 Sep; 291(3):H1158-69.
Score: 0.047
-
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis. 2004 Feb; 15(1):53-8.
Score: 0.040
-
In vitro ultrasound augmented clot dissolution--what is the optimal timing of ultrasound application? Cardiovasc Drugs Ther. 2002 Dec; 16(6):521-6.
Score: 0.037
-
Meta-Analysis of Brief Dual-Antiplatelet Therapy Duration After Percutaneous Coronary Intervention. Am J Cardiol. 2022 07 01; 174:182-184.
Score: 0.036
-
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
Score: 0.025
-
Spontaneous hemarthrosis following thrombolytic therapy for acute myocardial infarction. Int J Cardiol. 1993 Jul 15; 40(3):289-90.
Score: 0.019
-
Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheter Cardiovasc Interv. 2008 Oct 01; 72(4):488-97.
Score: 0.014
-
Synergism of aspirin and heparin with a low-frequency non-invasive ultrasound system for augmentation of in-vitro clot lysis. J Thromb Thrombolysis. 2003 Jun; 15(3):165-9.
Score: 0.010